Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Clinical trial NCT06788912 · RECRUITING

Trial details

NCT number: NCT06788912
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Neoplasm Malignant

Start date: 2025-03-20
Primary completion: 2032-02-06
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.